INTERWEST VENTURE MANAGEMENT CO - Q1 2022 holdings

$262 Million is the total value of INTERWEST VENTURE MANAGEMENT CO's 9 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 22.2% .

 Value Shares↓ Weighting
NewBRAZE INC$140,758,0003,394,219
+100.0%
53.76%
PMVP  PMV PHARMACEUTICALS INC$67,351,000
-9.9%
3,234,9110.0%25.73%
-41.8%
GKOS  GLAUKOS CORP$20,252,000
+30.1%
350,2640.0%7.74%
-15.9%
REAL  THE REALREAL$17,091,000
-37.5%
2,354,0800.0%6.53%
-59.6%
 SERA PROGNOSTICS$9,158,000
-44.8%
2,416,2410.0%3.50%
-64.3%
EIGR SellEIGER BIOPHARMACEUTICALS INC$4,656,000
+17.3%
560,990
-26.7%
1.78%
-24.2%
AGTC  APPLIED GENETIC TECHNOL CORP$1,503,000
-43.7%
1,404,5150.0%0.57%
-63.6%
VERO  VENUS CONCEPT INC$942,000
-15.9%
658,6570.0%0.36%
-45.6%
DARE  DARE BIOSCIENCE INC$92,000
-25.8%
62,0650.0%0.04%
-52.1%
AI ExitC3.AIcl a$0-866,774
-100.0%
-16.01%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-04-13
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
GLAUKOS CORP28Q3 202333.0%
EIGER BIOPHARMACEUTICALS INC24Q3 202217.7%
APPLIED GENETIC TECHNOL CORP24Q3 20226.7%
XENON PHARMACEUTICALS INC20Q3 20210.6%
CIDARA THERAPEUTICS INC19Q2 20214.5%
THE REALREAL18Q3 202362.6%
KALVISTA PHARMACEUTICALS INC17Q4 202010.8%
DARE BIOSCIENCE INC16Q3 20230.3%
MACROGENICS INC14Q1 202019.2%
PMV PHARMACEUTICALS INC13Q3 202367.5%

View INTERWEST VENTURE MANAGEMENT CO's complete holdings history.

Latest filings
TypeFiled
1442024-02-27
13F-HR2023-10-20
13F-HR2023-07-21
13F-HR2023-04-27
13F-HR2023-01-31
13F-HR2022-10-25
13F-HR2022-08-02
13F-HR2022-04-13
13F-HR2022-01-25
13F-HR2021-10-19

View INTERWEST VENTURE MANAGEMENT CO's complete filings history.

Compare quarters

Export INTERWEST VENTURE MANAGEMENT CO's holdings